Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2024 13:00 ET | Source: DelveInsight Business Research LLP

Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight

New York, USA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight Rare genetic disorders affect approximately 1 in...
July 09, 2024 07:57 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024

ZyVersa welcomes one-on-one meetings at the HCW Kidney Conference on July 15, 2024.
May 15, 2023 09:07 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease

Published data demonstrate that a deficiency in cholesterol transporter ABCA1 increases deposition of cellular cholesterol, contributing to inflammation, cell death (apoptosis), and damage to the...
March 01, 2023 09:20 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference

CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for...
February 09, 2022 17:15 ET | Source: The Rosen Law Firm PA

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RETA

NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between...